EARN25

CVAC Soars on Bayer COVID-19 Vaccine Collaboration

The company hopes its vaccine will be as effective as that of its peers

Deputy Editor
Jan 7, 2021 at 10:05 AM
facebook X logo linkedin


The shares of CureVac BV (NASDAQ:CVAC) are soaring this morning, up 18.5% at $102.88 at last check. The company is partnering with Bayer for its experimental COVID-19 vaccine -- which is now in late-stage trials -- in a deal reminiscent of the one between Pfizer (PFE) and BioNTech (BNTX). CureVac hopes its vaccine will produce results as effective as those achieved by the aforementioned companies, as well as those of Moderna's (MRNA), while accelerating approval and distribution. 

Publicly traded as of August, CVAC has been falling from its Dec. 9 record high of $151.80 -- down nearly 24% in the last month. However, the $80 level has acted as support recently, and with help from the 60-day moving average today's bull gap has the stock on track for its fourth-straight win.  

Meanwhile, of the two analysts in coverage, one sports a "strong buy" on CVAC, while the other carries a tepid "hold" rating. Meanwhile, the 12-month consensus price target of $73 is a 27.4% discount to current levels.

 

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!